- Home
- MAX vs LRMR Comparison
MAX vs LRMR Comparison
Compare MAX & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAX | LRMR |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 491.1M | 455.8M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MAX | LRMR |
|---|---|---|
| Price | $9.74 | $3.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $15.43 | $14.40 |
| AVG Volume (30 Days) | 676.7K | ★ 1.3M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.81 | N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $1,113,600,000.00 | N/A |
| Revenue This Year | $17.31 | N/A |
| Revenue Next Year | $8.70 | N/A |
| P/E Ratio | $10.92 | ★ N/A |
| Revenue Growth | ★ 28.78 | N/A |
| 52 Week Low | $7.09 | $2.72 |
| 52 Week High | $14.70 | $6.42 |
Technical Indicators
Market Signals| Indicator | MAX | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 33.64 | 33.64 |
| Support Level | $9.41 | $3.02 |
| Resistance Level | $10.26 | $3.76 |
| Average True Range (ATR) | 0.55 | 0.20 |
| MACD | -0.06 | -0.07 |
| Stochastic Oscillator | 23.19 | 15.36 |
Price Performance
Historical ComparisonAbout MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that enables insurance carriers and distributors to target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It serves as a customer acquisition channel in property and casualty insurance, health insurance, and life insurance. The company operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.